Agios Pharmaceuticals reached a new high of $107.30 on 8 December after the San Francisco-based developer of drugs targeting cancer metabolism said Celgene extended the companies' partnership again following positive Phase I results in advanced hematological malignancies for AG-221.
Agios Pharmaceuticals reached a new high of $107.30 on 8 December after the San Francisco-based developer of drugs targeting cancer metabolism said Celgene extended the companies' partnership again following positive Phase I results in advanced hematological malignancies for AG-221.
Agios gained 1.2% based on the Celgene partnership extension and the AG-221 results revealed on 7 December at the 56th...
The late-stage biotech posted results from the maintenance extension portion of its Phase IIb QUALITY trial in which enobosarm reduced weight regain and helped preserve lean mass in patients who discontinued their semaglutide weight-loss treatment.
GSK tells Scrip about timelines for data expected from two Phase II trials for its Bharat Biotech-partnered shigella vaccine candidate, which puts it ahead of Limmatech/Valneva. Meanwhile, a global-first malaria vaccine, also partnered with Bharat, sees an over 50% price cut
The drugmaker announced positive topline results for the drug in hemophilia A and B patients with inhibitors, on top of the existing approval for patients without inhibitors.
